Secondary analysis of the results showed that in year 1 and 2, eyes with pre-proliferative retinopathy receiving anti-VEGF for DMO may experience improvement in retinopathy severity and all 3 agents were associated with low rates of DR progression. Here, VEGFA is linked to retinal disorder.